VAS
INDV icon

VR Advisory Services’s Indivior Pharmaceuticals INDV Stock Holding History

VR Advisory Services’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-199,997
Closed -$4.82M – 39
2025
Q3 		$4.82M Sell
199,997
-441,213
-69% -$9.23M 1.17% 16
2025
Q2 		$9.54M Hold
641,210
– – 2.54% 7
2025
Q1 		$6.01M Hold
641,210
– – 1.57% 12
2024
Q4 		$8.22M Hold
641,210
– – 2.05% 9
2024
Q3 		$6.32M Buy
+641,210
New +$7.51M 2.18% 11

Other funds holding INDV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

VR Advisory Services's INDV Position: Q4 2025 in Review

VR Advisory Services sold out of Indivior Pharmaceuticals (INDV) in Q4 2025, closing a stake of 199,997 shares — an estimated $4.82M sold.

VR Advisory Services first reported a position in INDV in Q3 2024 and held it in 5 quarters. The position peaked at $9.54M in Q2 2025. 259 funds tracked by Wall St. Rank hold INDV as of Q4 2025.

  • VR Advisory Services reported no remaining Indivior Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • VR Advisory Services sold 199,997 Indivior Pharmaceuticals shares in Q4 2025, an estimated $4.82M.
  • VR Advisory Services first reported a position in Indivior Pharmaceuticals in Q3 2024 and held it in 5 quarters.
  • VR Advisory Services's Indivior Pharmaceuticals position peaked at $9.54M in Q2 2025.
  • 259 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q4 2025.

Based on VR Advisory Services's 13F filing for Q4 2025, filed 17 Feb 2026.